ClinicalTrials.gg
CompletedNCT01304147Updated Feb 8, 2017Results posted

Intranasal Ketamine in Treatment-Resistant Depression

An interventional study of Ketamine and placebo in Major Depressive Disorder, sponsored by James Murrough. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by James Murrough · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Enrollment
57th of 89
20 · median 38
Started
2011
the only one that year
No phase
18 of 89
1 open now
Registered
5th of 89
by date
Lead sponsor
3 of 89
James Murrough

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 57th largest by enrollment, is the only one that started in 2011, is one of 18 with no phase, and was the 5th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • ketamine
  • depression
  • treatment resistance
  • intranasal, antidepressant
  • glutamate
  • NMDA receptor
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients, 21-65 years;
  2. Women of must agree to use a medically accepted means of for the duration of the study;
  3. Primary diagnosis of major depressive disorder as assessed by the SCID-P;
  4. Current depressive episode;
  5. History of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode;
  6. Subjects must have scored ≥ 30 on the IDS-C30 at Screening ≥ 24 at Treatment Day #1 and #2;
  7. Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an document;
  8. Subjects must be able to identify a family member, physician, or friend who will participate in the Treatment Contract and serve as an emergency contact.

Exclusion criteria

Exclusion Criteria:

  1. Women who plan to become pregnant, are pregnant or are breast-feeding;
  2. Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease;
  3. abnormal findings of laboratory parameters, physical examination, or ;
  4. Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, OCD, mental retardation, pervasive developmental disorders, or Tourette's syndrome;
  5. Drug or alcohol abuse or dependence within the preceding 6 months;
  6. Lifetime abuse or dependence on ketamine or phencyclidine;
  7. Patients judged by study investigator to be at high risk for suicide.
  8. Previous participation in a ketamine study at Mount Sinai
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ketamine

    Subjects randomized to this arm will receive the active study medication, intranasal ketamine.

    Drug: Ketamine

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive intranasal saline.

    Drug: placebo

Interventions

  • A single dose of intranasal ketamine up to 50 mg

  • Drugplacebo

    Single dose of saline intranasal

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    Number of patients meeting response criteria of \>=50% decrease in MADRS score from baseline , ie, difference in depressive symptoms using MADRS instrument, 24 hours following drug administration 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points.

    Time frame: 24 hours

Secondary outcomes

  1. Systematic Assessment for Treatment Emergent Effects (SAFTEE)

    This is a self-report measure for systematically assessing 48 possible adverse events. It documents their severity, relationship to study drug, and the action taken.

    Time frame: 2 weeks

07

Results

Posted Feb 8, 2017
Limitations and caveats
Small sample size. Ongoing treatment with psychotropic medication allowed at stable doses makes it difficult to distinguish an intrinsic effect of ketamine from benefits resulting from the combination of ketamine with other antidepressant agents.

Participant flow

Study participants were recruited from physician referrals, media advertisements, and an academic outpatient psychiatric clinic. All study treatments were performed at Mount Sinai Medical Center between April 2012 and June 2013.

First Intervention (7days)
Participant flow — First Intervention (7days)
MilestoneKetamine Then PlaceboPlacebo, Then Ketamine
Started1010
Completed1010
Not completed00
Washout (1 Day)
Participant flow — Washout (1 Day)
MilestoneKetamine Then PlaceboPlacebo, Then Ketamine
Started1010
Completed1010
Not completed00
Second Intervention (7days)
Participant flow — Second Intervention (7days)
MilestoneKetamine Then PlaceboPlacebo, Then Ketamine
Started1010
Completed99
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMontgomery-Asberg Depression Rating Scale (MADRS)

Number of patients meeting response criteria of \>=50% decrease in MADRS score from baseline , ie, difference in depressive symptoms using MADRS instrument, 24 hours following drug administration 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points.

Time frame:
24 hours
Reported as:
Number · participants
Montgomery-Asberg Depression Rating Scale (MADRS)
participantsKetaminePlacebo
Montgomery-Asberg Depression Rating Scale (MADRS)81
Statistical analysis
  • Ketamine vs Placebo · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 7.6 · 95% CI 3.9 to 11.3
SecondarySystematic Assessment for Treatment Emergent Effects (SAFTEE)

This is a self-report measure for systematically assessing 48 possible adverse events. It documents their severity, relationship to study drug, and the action taken.

Time frame:
2 weeks
Reported as:
Number · events
Systematic Assessment for Treatment Emergent Effects (SAFTEE)
eventsKetaminePlacebo
Systematic Assessment for Treatment Emergent Effects (SAFTEE)7957

Adverse events

Collected over within 24 hours following treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine—0/19 (0%)19/19 (100%)
Placebo—0/19 (0%)19/19 (100%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventKetaminePlacebo
Trouble sleepingGeneral disorders1/199/19
Feeling strange or unrealGeneral disorders8/190/19
Poor MemoryGeneral disorders7/192/19
Weakness or fatigueGeneral disorders6/191/19
Delayed or absent orgasmSocial circumstances5/190/19
Nightmares or other sleep disturbanceGeneral disorders2/195/19
Loss of sexual interestSocial circumstances4/191/19
Trouble concentratingGeneral disorders4/192/19
Problems with sexual arousalSocial circumstances4/193/19
Feeling drowsy or sleepyGeneral disorders3/194/19

Baseline characteristics

one participant data information missing for history of Psychotherapy, and history of Failed Antidepressant Medications.

Age, Continuous
Age, Continuous(years)Participants Treated
Mean48.0 ± 12.8
Gender
Gender(Participants)Participants Treated
Female10
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants Treated
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported1
Married
Married(participants)Participants Treated
yes6
no14
Employed
Employed(participants)Participants Treated
yes10
no10
Age of Onset
Age of Onset(years)Participants Treated
Mean21.4 ± 12.0
Illness Duration in Years
Illness Duration in Years(years)Participants Treated
Mean27.4 ± 13.7
Chronic
Chronic(participants)Participants Treated
yes9
no11

11 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York City, New York 10029, United States
09

References and documents

Publications

  • Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014 Dec 15;76(12):970-6. doi: 10.1016/j.biopsych.2014.03.026. Epub 2014 Apr 3. PubMed 24821196 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2011
First posted
Feb 25, 2011
Start
Oct 2011
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Feb 8, 2017
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01304147
Lead sponsor
James Murrough
Responsible party
James Murrough (Principal Investigator, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Feb 25, 2011
Start date
Oct 2011
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Feb 8, 2017
Last update
Feb 8, 2017

Study contacts

James W Murrough, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion